Overview
- The MHRA, which approved the single-dose 7.2mg Wegovy pen on Tuesday, replaced a three‑injection same‑day regimen with one weekly shot for adults with a BMI of 30 or higher.
- Novo Nordisk expects UK stock within four to six weeks and says the device will be available on private prescription ahead of any NHS rollout.
- The newly authorised pen uses an automatic dosing system with an integrated needle that locks after use to simplify administration.
- Regulators will keep monitoring safety and urge patients to report suspected side effects through the MHRA Yellow Card scheme, and NHS use requires a NICE cost‑effectiveness decision.
- Media reports cite trial data linking the higher dose to greater average weight loss, though some specialists caution the larger dose may bring more gastrointestinal side effects and higher costs.